Journal profile · CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
Stem Cell Research & Therapy
ISSN 1757-6512 · BioMed Central · ENGLAND · Founded 2010
Stem Cell Research & Therapy: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 7.83; fully open access; APC about USD 3,290; median 158 days to acceptance (143 articles, last 24 months); 763 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Stem Cell Research & Therapy is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Mesenchymal stem cell research, Pluripotent Stem Cells Research and Tissue Engineering and Regenerative Medicine, together about 46.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Aims and scope: Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies. An international peer-reviewed journal, it publishes high-quality open access research articles with a special emphasis on basic, translational and clinical research into stem cell therapeutics and regenerative therapies, including animal models and clinical trials. The journal also provides reviews, commentaries, reports and methods. Please note that we do not accept pre-clinical systematic reviews, case reports, or pre-clinical meta-analyses. Topics covered include, but are not limited to: Adult stem cells Animal models Biophysics and mechanobiology Cancer stem cells Cell culture and manufacture Clinical studies Disease modelling and drug screening Embryonic stem cells Ethical, legal and social aspects Genetics and epigenetics Genomics/proteomics/metabolomics related to stem cell therapy Germ cells Immunology and Related Cell-based Technology Induced pluripotent stem cells Regenerative medicine Stem cell differentiation, proliferation and migration Stem cell derived Biologics Stem cell therapy/transplantation Technologies Tissue engineering and biomaterials Tissue/organ-on-a-chip technologies
From the journal's Aims & Scope
Research area (LetPub): CELL BIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Timothy O'BrienPublisher website
Editorial board by country: 3 in mainland China (about 6%); most named United States 13, Japan 6, Ireland 5, Malaysia 4, Mainland China 3 (47 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mesenchymal stem cell researchMedicine29.1%
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology9.5%
- Tissue Engineering and Regenerative MedicineMedicine8%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology7.5%
- Cancer Cells and MetastasisMedicine3.2%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology3%
- Wound Healing and TreatmentsMedicine3%
- Neurogenesis and neuroplasticity mechanismsNeuroscience2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cell & Tissue Engineering | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Cell & Tissue Engineering | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Cell & Tissue Engineering | Zone 2 |
| Minor | Cell Biology | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.83LetPub ·
- Impact factor (publisher) 2025
- 7.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 8.4Publisher website ·
- CiteScore 2026-06
- 11.9LetPub ·
- SJR 2026-06
- 1.94LetPub ·
- SNIP 2026-06
- 1.5LetPub ·
- h-index
- 56LetPub ·
- h-index
- 181OpenAlex ·
- i10-index
- 3,999OpenAlex ·
- 2-year mean citedness
- 7.48OpenAlex ·
- Self-citation rate
- 7.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 726LetPub ·
- Downloads per year (publisher) 2025
- 7,100,000Publisher website ·
Articles by year OpenAlex count · 5,748 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 433 | 433 | 213 |
| 2025 | 763 | 763 | 5,263 |
| 2024 | 505 | 505 | 7,251 |
| 2023 | 383 | 383 | 8,664 |
| 2022 | 536 | 536 | 19,222 |
| 2021 | 609 | 609 | 26,492 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
158 daysMedian, submission to acceptance · P25–P75 116 days – 227 days
- Acceptance to online
- median 15 days (143 articles)
- Submission to online
- median 185 days
- Sample
- 143 articles with submission and acceptance dates (1,371 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Submission to first decision
- 15 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,790 / USD 3,290 / GBP 2,490 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,190 / EUR 2,690 / GBP 2,390 | — | — | |
| LetPub | GBP 2,290 / USD 3,090 / EUR 2,590 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers4, by deadline
- Immune re-programming and long-term effects mediated by mesenchymal stromal cell therapyDeadline
- Neural Stem Cell-derived EVs for Treating Neurological and Neurodegenerative DisordersDeadline
- Stem Cell–Driven Regeneration in Cardiovascular, Musculoskeletal and Immune SystemsDeadline
- Pluripotent stem cell-enabled therapies for neurological disordersDeadline
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2010
- ISSN
- 1757-6512
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Stem Cell Research & Therapy
What CAS zone is Stem Cell Research & Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Stem Cell Research & Therapy is in Zone 2 of Medicine, and in Zone 2 of the minor category Cell & Tissue Engineering / Cell Biology / Medicine, Research & Experimental; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Stem Cell Research & Therapy?
The latest impact factor listed by LetPub is 7.83; CiteScore 11.9, h-index 181.
How long does peer review take at Stem Cell Research & Therapy?
Based on the dates recorded on 143 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 158 days (interquartile range 116–227 days); authors report an average review time of over 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Stem Cell Research & Therapy based?
Of the 47 board members whose country the journal's board page names, 3 (about 6%) are in mainland China; the countries named most often are United States (13), Japan (6) and Ireland (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Stem Cell Research & Therapy?
According to LetPub and DOAJ records, Stem Cell Research & Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Stem Cell Research & Therapy open access, and what is the APC?
Stem Cell Research & Therapy is a fully open-access journal. APC about USD 3,290.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .